Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

EVER/TMC Mutation as Marker of the Risk of Cutaneous Carcinoma in Immunosuppressed Patients (EBVER/TMC)

This study has been completed.
Information provided by (Responsible Party):
Andreas Arnold, University Hospital, Basel, Switzerland Identifier:
First received: August 7, 2013
Last updated: December 3, 2014
Last verified: December 2014
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: May 2014
  Primary Completion Date: May 2014 (Final data collection date for primary outcome measure)